June 12, 2018 Issue of JAMA

June 12, 2018, Vol 319, No. 22, Pages 2249-2346

This Week in JAMA

Highlights

Abstract Full Text

free access has audio

JAMA. 2018;319(22):2249-2251. doi:10.1001/jama.2017.12405

Podcast: Wound Management in LE Open Fractures, Medications That Cause Depression, Screening ECG Guideline, and more.

Original Investigation

Effect of Negative Pressure Wound Therapy vs Standard Wound Management on 12-Month Disability Among Adults With Severe Open Fracture of the Lower Limb: The WOLLF Randomized Clinical Trial

Matthew L. Costa, PhD; Juul Achten, PhD; Julie Bruce, PhD; et al.

Abstract Full Text

free access

JAMA. 2018;319(22):2280-2288. doi:10.1001/jama.2018.6452

This randomized clinical trial compares the effects of negative pressure wound therapy vs standard wound management on disability, deep infections, and quality of life in patients with severe open fracture of the lower limb.

Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States

Dima Mazen Qato, PharmD, MPH, PhD; Katharine Ozenberger, MS; Mark Olfson, MD, MPH

Abstract Full Text

free access

JAMA. 2018;319(22):2289-2298. doi:10.1001/jama.2018.6741

This pharmacoepidemiological study uses NHANES data to investigate the prevalence of use by adults of medications with depression or suicidal symptoms as known adverse events and to analyze the associations between use of those drugs and clinical depression.

Preliminary Communication

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial

Ganesh Raghu, MD; Bernt van den Blink, MD, PhD; Mark J. Hamblin, MD; et al.

Abstract Full Text

free access

JAMA. 2018;319(22):2299-2307. doi:10.1001/jama.2018.6129

This randomized clinical trial compares the effects of recombinant human pentraxin 2, a monocyte differentiation inhibitor, vs placebo on changes in percent predicted forced vital capacity after 28 weeks in patients with idiopathic pulmonary fibrosis.

Editorial
Clinical Trials in Idiopathic Pulmonary Fibrosis in the 鈥淧osttreatment Era鈥�
Kevin F. Gibson, MD; Daniel J. Kass, MD

JAMA

Research Letter

Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death

Björn Pasternak, MD, PhD; Viktor Wintzell, MSc; Kari Furu, PhD; et al.

Abstract Full Text

free access

JAMA. 2018;319(22):2333-2335. doi:10.1001/jama.2018.6237

This pharmacoepidemiology study uses Swedish and Norwegian registry data to investigate associations between fluconazole use during pregnancy and subsequent stillbirth and neonatal death.

US Preventive Services Task Force

Recommendation Statement

Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force

Abstract Full Text

free access has audio

JAMA. 2018;319(22):2308-2314. doi:10.1001/jama.2018.6848

This 2018 Recommendation Statement from the US Preventive Services Task Force recommends against ECG screening for CVD in asymptomatic adults at low risk (D recommendation) and concludes that evidence is insufficient to assess the benefits and harms of screening in asymptomatic adults at intermediate or high risk (I statement).

Podcast: USPSTF Recommendation: Screening for Cardiovascular Disease Risk With Electrocardiography

Editorial
The Screening ECG and Cardiac Risks
Robert J. Myerburg, MD

JAMA
- Podcast: When Will It Stop? Clinicians Are Still Ordering Routine ECGs Despite Recommendations to the Contrary
Does Resting or Exercise Electrocardiography Assist Clinicians in Preventing Cardiovascular Events in Asymptomatic Adults?
Joseph S. Alpert, MD

JAMA Cardiol
Screening for Cardiovascular Disease Risk With Electrocardiography
R. Sacha Bhatia, MD, MBA; Paul Dorian, MD, MSc

JAMA Intern Med

Evidence Report

Screening for Cardiovascular Disease Risk With Resting or Exercise Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force

Daniel E. Jonas, MD, MPH; Shivani Reddy, MD, MSc; Jennifer Cook Middleton, PhD; et al.

Abstract Full Text

free access

JAMA. 2018;319(22):2315-2328. doi:10.1001/jama.2018.6897

This systematic review to support the 2018 US Preventive Services Task Force Recommendation Statement on screening for cardiovascular disease (CVD) risk with electrocardiography (ECG) summarizes published evidence on the benefits and harms of screening resting or ECG screening to prevent CVD events.

Editorial
The Screening ECG and Cardiac Risks
Robert J. Myerburg, MD

JAMA
- Podcast: When Will It Stop? Clinicians Are Still Ordering Routine ECGs Despite Recommendations to the Contrary
Does Resting or Exercise Electrocardiography Assist Clinicians in Preventing Cardiovascular Events in Asymptomatic Adults?
Joseph S. Alpert, MD

JAMA Cardiol
Screening for Cardiovascular Disease Risk With Electrocardiography
R. Sacha Bhatia, MD, MBA; Paul Dorian, MD, MSc

JAMA Intern Med

Viewpoint

The Ethics of Medicaid鈥檚 Work Requirements and Other Personal Responsibility Policies

Harald Schmidt, PhD; Allison K. Hoffman, JD

Abstract Full Text

JAMA. 2018;319(22):2265-2266. doi:10.1001/jama.2018.3384

This Viewpoint discusses the possible harms of controversial state-mandated work requirements for Medicaid beneficiaries and proposes safeguards the Centers for Medicare & Medicaid Services might put in place to minimize health risks to patients.

Management Reasoning: Beyond the Diagnosis

David A. Cook, MD, MHPE; Jonathan Sherbino, MD, MEd; Steven J. Durning, MD, PhD

Abstract Full Text

free access

JAMA. 2018;319(22):2267-2268. doi:10.1001/jama.2018.4385

This Viewpoint discusses management reasoning, ways in which it differs from diagnostic reasoning, and areas that require further research.

The Evolving Pharmaceutical Benefits Market

Kevin A. Schulman, MD; Barak D. Richman, JD, PhD

Abstract Full Text

JAMA. 2018;319(22):2269-2270. doi:10.1001/jama.2018.4269

This Viewpoint explains the role of pharmaceutical benefit managers (PBMs) in the United States drug and health care market, and the potential effects acquisitions of PBMs by health insurers could have on prices and drug availability.

Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry

Michael S. Sinha, MD, JD, MPH; Gregory D. Curfman, MD; Michael A. Carrier, JD

Abstract Full Text

JAMA. 2018;319(22):2271-2272. doi:10.1001/jama.2018.3478

This Viewpoint uses 3 recent legal antitrust cases filed by pharmaceutical companies against each other to identify mechanisms by which companies suppress competition and keep drug prices inflated, and emphasizes the role of antitrust law as a potentially positive means to open markets and increase access to affordable drugs.

A Piece of My Mind

The Art of Constructive Worrying

Chandy C. John, MD, MS

Abstract Full Text

JAMA. 2018;319(22):2273-2274. doi:10.1001/jama.2018.6670

In this medical narrative essay, the author recounts how he transforms oversights of patient evidence while making a diagnosis has helped him develop a strategy to use worry to his advantage.

Editorial

Clinical Trials in Idiopathic Pulmonary Fibrosis in the 鈥淧osttreatment Era鈥�

Kevin F. Gibson, MD; Daniel J. Kass, MD

Abstract Full Text

JAMA. 2018;319(22):2275-2276. doi:10.1001/jama.2018.6225

The Screening ECG and Cardiac Risks

Robert J. Myerburg, MD

Abstract Full Text

has audio

JAMA. 2018;319(22):2277-2279. doi:10.1001/jama.2018.6766

Podcast: When Will It Stop? Clinicians Are Still Ordering Routine ECGs Despite Recommendations to the Contrary

JAMA Insights

Clinical Update

Antithrombotic Therapy for Peripheral Artery Disease in 2018

Connie N. Hess, MD, MHS; William R. Hiatt, MD

Abstract Full Text

free access

JAMA. 2018;319(22):2329-2330. doi:10.1001/jama.2018.5422

This JAMA Clinical Update reviews CVD risk stratification of patients with peripheral artery disease (PAD) and current standards of practice for use of antiplatelet and anticoagulant therapies.

Medical News & Perspectives

Framingham at 70: What We鈥檝e Learned About Women and Heart Disease

Rebecca Voelker, MSJ

Abstract Full Text

has audio

JAMA. 2018;319(22):2259-2260. doi:10.1001/jama.2018.5069

In this Medical News article, the Framingham Heart Study鈥檚 director, Daniel Levy, MD, discusses women鈥檚 participation during the study鈥檚 70-year history.

Podcast: Framingham at 70: What We鈥檝e Learned About Women and Heart Disease

The JAMA Forum

A Breath of Bad Air: Cost of the Trump Environmental Agenda May Lead to 80鈥�000 Extra Deaths per Decade

David Cutler, PhD; Francesca Dominici, PhD

Abstract Full Text

free access

JAMA. 2018;319(22):2261-2262. doi:10.1001/jama.2018.7351

News From the Centers for Disease Control and Prevention

Uptick in Autism

Bridget Kuehn, MSJ

Abstract Full Text

JAMA. 2018;319(22):2264. doi:10.1001/jama.2018.6806

Synthetic Cannabidiol Poisoning

Bridget Kuehn, MSJ

Abstract Full Text

JAMA. 2018;319(22):2264. doi:10.1001/jama.2018.7219

Biotech Innovations

Normothermic Preservation Poised to Change Organ Transplants

Jennifer Abbasi

Abstract Full Text

JAMA. 2018;319(22):2263. doi:10.1001/jama.2018.7234

Stem Cell Implants for Age-Related Macular Degeneration

Jennifer Abbasi

Abstract Full Text

JAMA. 2018;319(22):2263. doi:10.1001/jama.2018.7447

Poetry and Medicine

Song for a Soldier

Ted McMahon, MD

Abstract Full Text

JAMA. 2018;319(22):2339. doi:10.1001/jama.2017.21349

JAMA Revisited

The Brain Drain

Abstract Full Text

JAMA. 2018;319(22):2340. doi:10.1001/jama.2017.12413

JAMA Patient Page

Screening for Cardiovascular Disease Risk With ECG

Jill Jin, MD, MPH

Abstract Full Text

free access

JAMA. 2018;319(22):2346. doi:10.1001/jama.2018.7311

This JAMA Patient Page describes the US Preventive Task Force鈥檚 recommendations on screening for cardiovascular disease risk using electrocardiography (ECG).

Comment & Response

Contributions of Screening and Treatment to Mortality From Breast Cancer

Hsiu-Hsi Chen, PhD

Abstract Full Text

JAMA. 2018;319(22):2335-2336. doi:10.1001/jama.2018.4238

Reducing Calories to Lose Weight

Kevin D. Hall, PhD; Dale A. Schoeller, PhD; Andrew W. Brown, PhD

Abstract Full Text

JAMA. 2018;319(22):2336-2337. doi:10.1001/jama.2018.4257

Contributions of Screening and Treatment to Mortality From Breast Cancer鈥擱eply

Sylvia K. Plevritis, PhD; Donald A. Berry, PhD; Jeanne S. Mandelblatt, MD, MPH

Abstract Full Text

JAMA. 2018;319(22):2336. doi:10.1001/jama.2018.4261

Reducing Calories to Lose Weight鈥擱eply

Eve Guth, MD

Abstract Full Text

JAMA. 2018;319(22):2337-2338. doi:10.1001/jama.2018.4265

Patient Education on Patellofemoral Pain

Christian J. Barton, PhD; Sinéad Holden, PhD; Michael Skovdal Rathleff, PhD

Abstract Full Text

JAMA. 2018;319(22):2338. doi:10.1001/jama.2018.4458

Patient Education on Patellofemoral Pain鈥擱eply

Jill Jin, MD, MPH; Emily Jones, MD

Abstract Full Text

JAMA. 2018;319(22):2338. doi:10.1001/jama.2018.4474

November 2024 - July 1883

Decade

Year

Issue

June 12, 2018, Vol 319, No. 22, Pages 2249-2346

Recommendation Statement

Evidence Report

Clinical Update

Latest from the USPSTF